Crinetics Pharmaceuticals, Inc.
CRNX
$30.93
$0.842.79%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -115.64M | -96.77M | -80.60M | -76.83M | -74.06M |
| Total Depreciation and Amortization | 959.00K | 925.00K | 788.00K | 770.00K | 753.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 22.23M | 16.93M | 15.44M | 15.39M | 16.28M |
| Change in Net Operating Assets | 6.60M | -9.54M | -308.00K | -2.15M | 9.38M |
| Cash from Operations | -85.85M | -88.45M | -64.67M | -62.82M | -47.64M |
| Capital Expenditure | -3.20M | -1.24M | -1.03M | -528.00K | -955.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 41.16M | -84.72M | -541.06M | 21.13M | -52.69M |
| Cash from Investing | 37.95M | -85.96M | -542.09M | 20.60M | -53.64M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 7.06M | 4.44M | 586.18M | 58.83M | 4.68M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -32.14M | -1.50M | 2.85M |
| Cash from Financing | 7.06M | 4.44M | 554.04M | 57.33M | 7.52M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -40.84M | -169.98M | -52.72M | 15.11M | -93.76M |